CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Daclizumab beta

Last Updated: October 18, 2016
Result type: Reports
Project Number: SR0508-000
Product Line: Reimbursement Review

Generic Name: Daclizumab beta

Brand Name: Zinbryta

Manufacturer: Biogen Canada Inc.

Therapeutic Area: Multiple Sclerosis, relapsing-remitting

Indications: Multiple Sclerosis, relapsing

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: June 20, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions